fb-pixel tracker
News

Caris Life Sciences Data Highlighted During ASCO Presentation Showing Cascading Effects of Tumor Repair Gene Mutations and Tumor Cell Phenotype

Caris’ robust database enables evaluation of more than 24,000 tumor specimens to identify correlations with mismatch repair gene mutations, other DNA repair gene mutations and tumor phenotypes Oral presentation at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting IRVING, Tex., June 4, 2018 – Caris Life Sciences®, a leading innovator in molecular science … Continued

Caris Life Sciences Announces First Ph.D. Recipient from Educational Collaboration with Arizona State University

Private Industry / Academic Collaboration Fosters Real-World Innovative Research IRVING, Texas, May 22, 2018 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that its first employee has received his Ph.D. from a collaborative research program with Arizona State University (ASU). The Molecular and … Continued

Caris Life Sciences to Present New Molecular Findings at the 2018 ASCO Annual Meeting

Caris Data Further Advances Molecular Understandings of Cancer to Enable the Delivery of Precision Medicine IRVING, Tex., May 21, 2018 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the acceptance of 10 abstracts, including one oral presentation, by the American Society of Clinical … Continued

Piedmont Cancer Joins Caris Life Sciences’ Precision Oncology Alliance

Piedmont Cancer becomes the 22nd institution to join the Precision Oncology Alliance IRVING, Texas, April 24, 2018 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that Piedmont Cancer has joined Caris’ Precision Oncology Alliance (POA) as its 22nd member and will work with … Continued

Caris Life Sciences Announces Published Results Showing that its ADAPT Biotargeting System Effectively Stratified Breast Cancer Patients Based on Their Benefit from Trastuzumab Treatment (Herceptin)

Data featured in Nature Communications showed ADAPT Biotargeting System significantly out-performed industry standard HER2 testing IRVING, Texas, March 23, 2018 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced publication of an article that demonstrated the Company’s proprietary ADAPT Biotargeting System (ADAPT) significantly out-performed … Continued

Caris Life Sciences Announces Presentations at 2018 SGO Annual Meeting on Women’s Cancer Highlighting Tumor Profiling for Immunotherapy Advances

Presentations demonstrate utility of tumor profiling to guide individualized treatment Relationship between immunotherapy associated biomarkers, MSI, TMB and PD-L1, explored across more than 5,000 gynecologic cancer cases IRVING, Texas, March 22, 2018 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the acceptance of … Continued

Caris Life Sciences Applauds CMS Decision to Reaffirm the Longstanding Coverage for Its Next-Generation Sequencing Assay

Medicare patients remain covered and continue to have access to Caris’ NGS assay for solid tumors that includes 592 genes, Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB) IRVING, Texas, March 21, 2018 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today confirmed that the … Continued

Caris Life Sciences Announces Published Results Validating its Next-Generation Sequencing Platform to Detect Microsatellite Instability and Comparing Immunotherapy Associated Biomarkers across 11,000 Patients

Study validates next-generation sequencing approach compared to the current standard method of PCR fragment analysis on more than 2,000 cases Relationship between immunotherapy associated biomarkers, MSI, TMB and PD-L1, explored across an unprecedented 11,348 cases Highly relevant due to recent FDA approval of pembrolizumab to treat MSI-H regardless of tumor origin IRVING, Texas, Feb. 14, … Continued

Caris Life Sciences to Present at the 36th Annual J.P. Morgan Healthcare Conference

IRVING, Texas, Jan. 2, 2018 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that David D. Halbert, Chairman and Chief Executive Officer, and David Spetzler, M.S., Ph.D., M.B.A., President and Chief Scientific Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference … Continued

1 2 3 4 18

About Our News

Search to find the latest new about Caris Molecular Intelligence®, sign up for news alerts, and be sure to follow us on social media.